Showing results (31-40 of 98) with videos related to
Sort By:
Pageof 10
BJC Reports|August 18, 2025
Hidden costs and unmet supportive care needs among individuals with experience of breast cancer and their carers in the United KingdomSzeyi Ng, Lucy S Kilburn, Hilary Stobart, et al.Breast Cancer Research and Treatment|March 29, 2013
Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancerJohn M S Bartlett, Roger A'hern, Tammy Piper, et al.Nature Communications|March 3, 2018
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancerBen O'Leary, Sarah Hrebien, James P Morden, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 25, 2025
Five-year trends and baseline predictors of patient-reported adverse events following breast radiotherapy with a boost in the IMPORT HIGH phase III randomised controlled trialSzeyi Ng, Lucy S Kilburn, Anna M Kirby, et al.The Lancet. Oncology|February 3, 2007
Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled studyRobert E Coleman, Linda M Banks, Samia I Girgis, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapyJohn M S Bartlett, Ian O Ellis, Mitch Dowsett, et al.Research Involvement and Engagement|July 21, 2018
Patient advocate involvement in the design and conduct of breast cancer clinical trials requiring the collection of multiple biopsiesLeona M Batten, Indrani Subarna Bhattacharya, Laura Moretti, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2014
Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)Alexandra Leary, Abigail Evans, Stephen R D Johnston, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 6, 2016
Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward TrialA Murray Brunt, Duncan Wheatley, John Yarnold, et al.Ebiomedicine|July 19, 2025
Short-duration preoperative endocrine therapy alters molecular profiles to predict favourable outcome in ER+/HER2+ early breast cancer: a POETIC translational studyMilana Bergamino Sirvén, Elena López-Knowles, Xixuan Zhu, et al.Pageof 10